scholarly journals Determination of O6-Methylguanine in Dried Blood Spot of Breast Cancer Patients After Cyclophosphamide Administration

Heliyon ◽  
2021 ◽  
pp. e07558
Author(s):  
Yahdiana Harahap ◽  
Athalia Theda Tanujaya ◽  
Farhan Nurahman ◽  
Aurelia Maria Vianney ◽  
Denni Joko Purwanto
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Dried Blood Spot ◽  
Breast Cancer Patients ◽  
Cyclophosphamide Administration ◽  
Blood Spot

scholarly journals ANALYSIS OF DOXORUBICIN AND DOXORUBICINOL IN DRIED BLOOD SPOT OF BREAST CANCER PATIENTS FOR MONITORING THE CARDIOTOXICITY OF DOXORUBICIN

2020 ◽  
pp. 21-25
Author(s):  
YAHDIANA HARAHAP ◽  
SABRINA NUR AMALIA ◽  
ALDHI ANARTA ◽  
RAMADHAN
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Gradient Elution ◽  
Ultra Performance Liquid Chromatography ◽  
Incidence Rates ◽  
Dried Blood Spot ◽  
Precipitation Method ◽  
Breast Cancer Patients ◽  
Acquity Uplc ◽  
Blood Spot

Objective: This study aimed to analyze doxorubicin and doxorubicinol levels in Dried Blood Spot (DBS) from 25 breast cancer patients who received doxorubicin in their therapeutic regiment. Methods: DBS samples were extracted by protein precipitation method and analyzed using Ultra Performance Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS), with the Acquity UPLC BEH C18 Waters chromatography column (2.1 x 100 mm x 1.7 μm). The mobile phase consisted of 0.1% acetic acid (eluent A) and acetonitrile (eluent B) with gradient elution; the flow rate was 0.15 ml/min and runtime, 7 min. This method was linear within the concentration range of 10–200 ng/ml for doxorubicin and 4–100 ng/ml for doxorubicinol. Result: The analysis results showed that doxorubicin levels were in the range of 11.01 ng/ml to 93.75 ng/ml and doxorubicinol was 5.80 ng/ml to 58.57 ng/ml. Conclusion: Cumulative doses of all patients were in the range of 49.11 mg/m2to 303.70 mg/m2, which have cardiomyopathy incidence rates<4%.

scholarly journals METHOD DEVELOPMENT ON ANALYSIS CYCLOPHOSPHAMIDE AND 4-HYDROXYCYCLOPHOPHAMIDE IN DRIED BLOOD SPOT AND ITS APPLICATION IN BREAST CANCER PATIENTS

2020 ◽  
pp. 119-125
Author(s):  
YAHDIANA HARAHAP ◽  
NURLITA GUSTIYANTI ◽  
AYU EGAHMUSTIKA SUNANTO ◽  
HARMITA ◽  
DENNIJOKO PURWANTO
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Therapeutic Drug Monitoring ◽  
Cancer Patients ◽  
Drug Monitoring ◽  
Dried Blood Spot ◽  
Therapeutic Drug ◽  
Breast Cancer Patients ◽  
Validation Parameters ◽  
Blood Spot

Objective: To develop the method for the simultaneous analysis of cyclophosphamide and 4-hydroxycyclophosphamide (4-OHCP) in Dried Blood Spot (DBS) using Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) and its application in breast cancer patients for therapeutic drug monitoring. Methods: Sample preparation used protein precipitation with methanol and acetonitrile (2:1 v/v). The separation was conducted using 1.7μm (2.1 x 100 mm) Waters AcquityTM UPLC C18 column; mobile phase consists of 0.01% formic acid and methanol (50:50 v/v) with isocratic elution, column temperature 30 °C, flow rate 0.3 ml/min and hexamethylphosphoramide (HMP) used as an internal standard. Analysis was performed by a triple quadrupole mass spectrometry with a positive ion mode of Electrospray Ionization. Cyclophosphamide was detected at m/z 260.968>139.978, 4-OHCP at m/z 338.011>224.979, and HMP at m/z 180.17>92.08. The method was applied to quantify cyclophosphamide and 4-OHCP in DBS of breast cancer patients. Blood samples were collected at 2 and 4 h after cyclophosphamide administration for therapeutic drug monitoring. Results: The method was linear in the range of 50–30.000 ng/ml for cyclophosphamide and 10–1000 ng/ml for 4-OHCP. Lower Limit of Quantification (LLOQ) concentration of cyclophosphamide was 50 ng/ml and 4-OHCP was 10 ng/ml. Accuracy and precision within-run and between-run met the requirements with % diff and CV, not exceeding ±15% and not more than ±20% for LLOQ concentration. The results from DBS samples of cancer patients showed that the level of cyclophosphamide was in the range of 6045.980 ng/ml to 37024.403 ng/ml and 4-OHCP was in the range 33.155 ng/ml to 246.362 ng/ml. Conclusion: The developed method met the requirements of all validation parameters under the Guideline on Bioanalytical Method Validation by the European Medicines Agency in 2011. Method can be applied on DBS of cancer patients and the results showed that cyclophosphamide and 4-OHCP was detected on 17 samples of breast cancer patients. This can be one of the parameters for therapeutic drug monitoring.

scholarly journals RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients

2006 ◽  
Vol 17 (3) ◽  
pp. 424-428 ◽  
Author(s):  
L. Mercatali ◽  
V. Valenti ◽  
D. Calistri ◽  
S. Calpona ◽  
G. Rosti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Breast Cancer Patients ◽  
Rt Pcr ◽  
Healthy Donors

Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography

Talanta ◽  
2015 ◽  
Vol 131 ◽  
pp. 535-540 ◽  
Author(s):  
Juan Peris-Vicente ◽  
Enrique Ochoa-Aranda ◽  
Devasish Bose ◽  
Josep Esteve-Romero
Keyword(s):  
Breast Cancer ◽  
Liquid Chromatography ◽  
Cancer Patients ◽  
Micellar Liquid Chromatography ◽  
Plasma Samples ◽  
Breast Cancer Patients

scholarly journals Determination of the Complex between Urokinase and Its Type-1 Inhibitor in Plasma from Healthy Donors and Breast Cancer Patients

1999 ◽  
Vol 45 (8) ◽  
pp. 1206-1213 ◽  
Author(s):  
Anders N Pedersen ◽  
Nils Brünner ◽  
Gunilla Høyer-Hansen ◽  
Peter Hamer ◽  
David Jarosz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Detection Limit ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Healthy Donors ◽  
Pai 1 ◽  
Healthy Females ◽  
Assay Detection

Abstract Background: The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) is formed exclusively from the active forms of these components; thus, the complex concentration in a biological sample may reflect the ongoing degree of plasminogen activation. Our aim was to establish an ELISA for specific quantification of the uPA:PAI-1 complex in plasma of healthy donors and breast cancer patients. Methods: A kinetic sandwich format immunoassay was developed, validated, and applied to plasma from 19 advanced-stage breast cancer patients, 39 age-matched healthy women, and 31 men. Results: The assay detection limit was &lt;2 ng/L, and the detection of complex in plasma was validated using immunoabsorption, competition, and recovery tests. Eighteen cancer patients had a measurable complex concentration (median, 68 ng/L; range, &lt;16 to 8700 ng/L), whereas for healthy females and males the median signal values were below the detection limit (median, &lt;16 ng/L; range, &lt;16 to 200 ng/L; P &lt;0.0001). For patient plasma, a comparison with total uPA and PAI-1 showed that the complex represented a variable, minor fraction of the uPA and PAI-1 concentrations of each sample. Conclusion: The reported ELISA enables detection of the uPA:PAI-1 complex in blood and, therefore, the evaluation of the complex as a prognostic marker in cancer.

Determination of Serum Methylparaben Concentrations of Bangladeshi Breast Cancer Patients by RP-HPLC

2017 ◽  
Vol 7 (5) ◽  
pp. 589-595 ◽  
Author(s):  
Sanjida Afrin ◽  
Hasina Akhter Simol ◽  
Gazi Nurun Nahar Sultana ◽  
Md. Sazedul Islam ◽  
Papia Haque ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Rp Hplc
Sign in / Sign up

Export Citation Format

Share Document